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Long-term eﬀ ects of lithium on renal, thyroid, and 
parathyroid function: a retrospective analysis of 
laboratory data
Brian Shine, Rebecca F McKnight, Laurence Leaver, John R Geddes
Summary
Background Lithium is a widely used and highly eﬀ ective treatment for mood disorders, but causes poorly characterised 
adverse eﬀ ects in kidney and endocrine systems. We aimed to analyse laboratory information system data to determine 
the incidence of renal, thyroid, and parathyroid dysfunction associated with lithium use.
Methods In a retrospective analysis of laboratory data from Oxford University Hospitals National Health Service Trust 
(Oxfordshire, UK), we investigated the incidence of renal, thyroid, and parathyroid dysfunction in patients (aged 
≥18 years) who had at least two creatinine, thyrotropin, calcium, glycated haemoglobin, or lithium measurements 
between Oct 1, 1982, and March 31, 2014, compared with controls who had not had lithium measurements taken. We 
used survival analysis and Cox regression to estimate the hazard ratio (HR) for each event with lithium use, age, sex, 
and diabetes as covariates.
Findings Adjusting for age, sex, and diabetes, presence of lithium in serum was associated with an increased risk of 
stage three chronic kidney disease (HR 1·93, 95% CI 1·76–2·12; p<0·0001), hypothyroidism (2·31, 2·05–2·60; 
p<0·0001), and raised total serum calcium concentration (1·43, 1·21–1·69; p<0·0001), but not with hyperthyroidism 
(1·22, 0·96–1·55; p=0·1010) or raised adjusted calcium concentration (1·08, 0·88–1·34; p=0·4602). Women were at 
greater risk of development of renal and thyroid disorders than were men, with younger women at higher risk than 
older women. The adverse eﬀ ects occurred early in treatment (HR <1 for length of treatment with lithium). Higher 
than median lithium concentrations were associated with increased risk of all adverse outcomes.
Interpretation Lithium treatment is associated with a decline in renal function, hypothyroidism, and hypercalcaemia. 
Women younger than 60 years and people with lithium concentrations higher than median are at greatest risk. 
Because lithium remains a treatment of choice for bipolar disorder, patients need baseline measures of renal, thyroid, 
and parathyroid function and regular long-term monitoring.
Funding None.
Copyright © Shine et al. Open Access article distributed under the terms of CC BY-NC-ND.
 Introduction
Mood disorders aﬀ ect at least 350 million individuals 
worldwide and represent a substantial global burden of 
disease.1 In high-income countries, unipolar depression is 
the leading cause of disability and morbidity.1 Lithium is a 
widely used and eﬀ ective treatment for mood disorders, 
protecting against both depression and mania and 
reducing risk of suicide.2–5 However, a narrow therapeutic 
index, which necessitates routine monitoring of serum 
concentrations, is one of the clinical disadvantages of 
lithium in practice. Lithium can also adversely aﬀ ect the 
kidneys, thyroid, and parathyroid glands, so regular mon-
itoring of renal and endocrine function is recommended.6
The renal eﬀ ects of lithium were ﬁ rst reported more than 
30 years ago,7,8 and investigators have begun characterising 
and quantifying these eﬀ ects.6,9–11 Lithium causes three types 
of renal impairment: acute toxic eﬀ ects, nephrogenic 
diabetes insipidus, and chronic renal dysfunction. Results 
of a meta analysis6 of studies addressing lithium toxicity 
showed that little evidence existed for a clinically signiﬁ cant 
reduction in renal function in most patients, and the risk of 
end-stage renal failure is low. However, substantial 
uncertainty remains because most of these studies were of 
short duration and unable to detect long-term eﬀ ects. The 
risk of end-stage renal failure with lithium therapy has been 
estimated to be 0·5–1·0%; the risk factors for development 
of end-stage renal failure or for an accelerated decline in 
renal function remain unknown.12,13 Similarly, lithium 
therapy has been shown to disturb thyroid and parathyroid 
endocrine systems, but long-term follow-up studies are 
needed to characterise the incidence and risk factors.
We aimed to use laboratory information system data 
to determine the incidence of renal, thyroid, and 
parathyroid dysfunction caused by lithium use and to 
determine the strength of any associations noted.
Methods
Study design and participants
In this retrospective cohort study we extracted routinely 
collected data from the laboratory information system of 
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the Clinical Biochemistry Department, Oxford University 
Hospitals NHS Trust. The laboratory performs routine 
tests for primary and secondary care for about 
650 000 people in Oxfordshire, UK, and parts of neigh-
bouring counties (Buckinghamshire, Northampton shire). 
The information system has been in operation continuously 
since 1985. Until 2003, the laboratory covering the northern 
part of Oxfordshire had a diﬀ erent laboratory system, data 
from which were not included in this analysis.
The study cohort included all patients in the laboratory 
information system aged at least 18 years and with at least 
two measurements of serum creatinine, thyrotropin, 
calcium, glycated haemoglobin (HbA1c), or lithium taken 
between Oct 1, 1985, and March 31, 2014. The main 
exposure was lithium therapy (deﬁ ned as more than 
two detectable serum lithium measurements), and all 
other patients of the same sex and age group but with no 
lithium measurements were non-exposed controls. We 
assumed non-Afro–Caribbean ethnicity because ethnicity 
is not recorded on the requests or our system.
No speciﬁ c ethical approval was sought. BS is the 
keeper of the laboratory information system data, and all 
information used within the study was anonymised and 
not traceable to a single individual. The results of the 
analysis were not used to change clinical management 
in the patients studied.
Procedures
We estimated glomerular ﬁ ltration rate from age, sex, 
and serum creatinine concentration with the MDRD 
4-parameter equation (a UK standard for calculation of 
estimated glomerular ﬁ ltration rate). For measurements 
of serum calcium concentration, if albumin concen-
tration was measured on the same specimen, we adjusted 
the calcium concentration to an albumin concentration 
of 40 g/L with a factor of 0·02 mmol/L per g albumin/L 
diﬀ erence from 40 g/L. We used the system database 
language (Intersystems Caché Objectscript) to deﬁ ne for 
every patient the ﬁ rst and last dates of measurement for 
each parameter, and the date (if applicable) when the 
Sex Number of 
patients
Age, years Diabetes 
prevalence (%)
Measurements 
per patient
Lithium 
measurements per 
patient
Overall
Women ·· 332 710 50 (34–67) 6·4% ·· ··
Men ·· 282 626 55 (40–67) 9·7% ·· ··
Decline in renal function (estimated glomerular ﬁ ltration rate <60 mL/min per 1·73 m²)
Control Female 265 200 46 (32–62) 6·1% 6 (3–13) 0
Control Male 236 475 52 (39–64) 9·7% 6 (3–14) 0
Lithium Female 1422 43 (31–58) 8·6% 18 (7–33) 8 (3–21)
Lithium Male 1065 44 (33–57) 10·9% 15 (7–29) 7 (2–20)
Hypothyroidism (thyrotropin activity >5·5 mU/L)
Control Female 152 992 50 (36–67) 8·9% 3 (2–6) 0
Control Male 95 791 58 (44–70) 17·5% 4 (2–6) 0
Lithium Female 1316 48 (35–64) 8·0% 11 (5–18) 9 (4–23)
Lithium Male 955 48 (36–62) 12·6% 9 (4–15) 9 (4–22)
Hyperthyroidism (thyrotropin activity <0·2 mU/L)
Control Female 142 505 49 (35–67) 8·9% 3 (2–6) 0
Control Male 91 530 57 (44–70) 17·5% 3 (2–5) 0
Lithium Female 1052 49 (35–66) 7·9% 9 (4–16) 8 (3–21)
Lithium Male 864 49 (37–61) 12·6% 8 (4–14) 8 (3–21)
Parathyroid function (total serum calcium concentration >2·6 mmol/L)
Control Female 120 829 60 (44–75) 8·9% 4 (2–7) 0
Control Male 105 210 62 (48–74) 17·5% 4 (2–8) 0
Lithium Female 1013 54 (42–69) 7·9% 5 (3–10) 10 (3–26)
Lithium Male 623 57 (42–69) 12·6% 5 (3–9) 10 (3–23)
Parathyroid function (adjusted serum calcium concentration >2·6 mmol/L)
Control Female 125 133 61 (44–75) 10·2% 4 (2–8) 0
Control Male 107 391 62 (48–73) 13·4% 4 (2–9) 0
Lithium Female 1085 55 (42–70) 12·6% 5 (3–10) 11 (3–26)
Lithium Male 652 57 (42–68) 16·0% 5 (3–9) 10 (3–24)
Data are median (IQR) unless otherwise stated.
Table 1: Patient characteristics 
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patient ﬁ rst had a decline in renal function (estimated 
glomerular ﬁ ltration rate <60 mL/min per 1·73 m²; stage 
three chronic kidney disease), hypothyroidism 
(thyrotropin activity >5·5 mU/L), hyperthyroidism 
(thyrotropin activity <0·2 mU/L), or a raised total or 
adjusted serum calcium concentration (>2·6 mmol/L). 
Patients with an abnormal estimated glomerular 
ﬁ ltration rate, thyrotropin activity, or calcium 
concentration at the ﬁ rst measurement or who had no 
further measurements of the parameter being studied 
were excluded. For lithium measurements, we recorded 
the ﬁ rst and last dates of measurement, the number of 
measurements ever requested, and the median and 
maximum lithium concentrations. For HbA1c we 
inspected all measure ments, and deﬁ ned any result of 
greater than 6·5% (48 mmol/mol) as consistent with a 
diagnosis of diabetes.
Because laboratory investigation forms do not include 
the dose or regime of lithium treatment, no information 
as to dose or lithium formulation was available. The 
primary psychiatric diagnosis, polypharmacy, and medical 
comorbidities of the patient were unknown, although 
potential confounding by diabetes was investigated in 
the analysis.
Statistical analysis
We used R version 3.10 for statistical analysis, including 
the survival, ggplot2, plyr, and dplyr library modules.14 
We performed Cox proportional hazards analyses, with 
lithium use, age (years), sex, and diabetes as covariates. 
For each analysis, we checked for the signiﬁ cance of 
the two-parameter interaction, that is, the likelihood 
that signiﬁ cantly diﬀ erent eﬀ ects existed for diﬀ erent 
age or sex groups. The output of each analysis is a 
summary giving the relative risk for the factors. We 
used a conventional signiﬁ cance level of p<0·05, and 
did not adjust for multiple comparisons. We drew 
graphs of survival curves with an adaptation of the 
ggplot2 function “createSurvivalFrame”. We tested the 
proportional hazards assumption for each analysis by 
plotting log(–log(survival)) against log(time).
Role of the funding source
The sponsor of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. BS and RFM had full access to all 
the data. BS had ﬁ nal responsibility for the decision to 
submit for publication and is guarantor.
Results
The laboratory information system contained data for 
4678 patients who had serum lithium concentrations 
measured once (2795 [60%] of whom had more than 
one measurement) and 689 228 controls (table 1). 
Figure 1 shows the distributions of number of lithium 
measure ments (range 2–162), and ﬁ gure 2 shows the 
distribution of time between ﬁ rst and last lithium 
measurements (median 3·0, IQR 0·7–8·7 years, max 
28 years). In patients with more than one lithium 
measurement, the median concentration was 0·6 
(0·5–0·7) mmol/L.
After adjustment for age (cut-oﬀ  60 years), sex, and 
evidence of diabetes, presence of lithium was 
signiﬁ cantly associated with stage three chronic kidney 
disease, hypothyroidism, and high total calcium con-
centration, but not with development of hyperthyroidism 
or high adjusted calcium concentration (table 2). Table 2 
shows the hazard ratios for main factors (presence of 
lithium, age >60 years, sex, and diabetes) and the 
interaction terms (age >60 years with sex, age >60 years 
with lithium, and sex with lithium). The last four rows 
show the hazard ratios for the endpoint of interest for 
four diﬀ erent age and sex groups (age cut-oﬀ  60 years 
and presence or absence of lithium) adjusted for 
evidence of diabetes. Kaplan-Meier estimates for 
association of lithium with development of stage 3 
chronic kidney disease (ﬁ gure 3) and hypothyroidism 
(ﬁ gure 4) in subgroups show signiﬁ cant diﬀ erences 
depending on age, sex, and evidence of diabetes. For 
renal decline, young women without diabetes show the 
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largest eﬀ ect, with smaller eﬀ ects in older men and 
women, and no increase in risk in younger men or in 
any of the subgroups with diabetes, perhaps because 
the numbers of patients with diabetes and taking 
lithium were small (table 2, ﬁ gure 3). For development 
of hypothyroidism, the eﬀ ect of lithium was signiﬁ cant 
in all four age and sex subgroups, but greatest in 
younger women. However, in patients with evidence of 
diabetes, the only association was in older women 
(table 2, ﬁ gure 4). For elevated total calcium con-
centration, there was a positive association in all 
subgroups except for younger men (table 2).
In patients receiving lithium, median serum lithium 
concentrations higher than the overall median were 
associated with declines in renal function (estimated 
glomerular ﬁ ltration rate <60 mL/min per 1·73 m²), 
high thyrotropin activity, high total serum calcium 
concentration, and high adjusted serum calcium 
concentration (table 3). Length of time between ﬁ rst and 
last lithium measurements greater than the median was 
associated with a reduced likelihood of each these 
outcomes (all HR <1; table 3), indicating that the eﬀ ect 
was more likely to occur early. In patients receiving 
lithium, no association between the development of any 
of the endpoints and diabetes was found (table 3). The 
distributions of median serum lithium concentrations 
were similar in men and women, and were not 
signiﬁ cantly diﬀ erent.
Discussion
Our results suggest that presence of lithium in serum is 
strongly associated with a decline in renal function and 
hypothyroidism, and less strongly with high total calcium 
concentrations. Young women had higher hazard ratios 
than other groups, suggesting that they are at greatest 
risk of renal disorder and hypothyroidism. High median 
serum lithium concentration seems to be a risk factor for 
all long-term complications of lithium use, although 
length of lithium treatment has a negative association, 
which suggests that the eﬀ ects have rapid onset once 
patients start taking lithium.
In a large systematic review,6 we reported that lithium 
use did not cause a clinically signiﬁ cant decline in renal 
function. However, as we noted, a limitation of this 
review was that the included studies were very short-term, 
typically lasting 1–2 years. Our present results suggest 
that a patient receiving lithium is at high risk of 
developing at least stage three chronic kidney disease 
(table 2), and that the eﬀ ect is observed quite soon after 
initiation of lithium treatment. Although stage three 
chronic kidney disease does not necessarily represent a 
clinically relevant decline in renal function, a subset of 
these patients might develop end-stage renal failure. We 
did not explore this possibility further in this study, but 
other studies6,11–13,15—including whole-country studies in 
Scandinavia and Australia—suggest that progression to 
end-stage renal failure is uncommon, with an absolute 
Decline in renal 
function
Hypothyroidism Hyperthyroidism Total calcium 
concentration 
>2·6 mmol/L
Adjusted calcium 
>2·6 mmol/L
Composite endpoint
Lithium 1·93 (1·76–2·12); 
p<0·0001
2·31 (2·05–2·60); 
p<0·0001
1·21 (0·96–1·55); 
p=0·1010
1·43 (1·21–1·69); 
p<0·0001
1·08 (0·88–1·34); 
p=0·4602
1·76 (1·58–1·97) 
p<0·0001
Age 
>60 years
5·23 (5·14–5·31); 
p<0·0001
1·75 (1·70–1·81); 
p<0·0001
1·97 (1·88–2·07); 
p<0·0001
1·24 (1·20–1·29); 
p<0·0001
1·83 (1·77–1·90); 
p<0·0001
3·25 (3·18–3·33) 
p<0·0001
Male 1·03 (1·02–1·05); 
p=0·0003
0·56 (0·53–0·58); 
p<0·0001
0·55 (0·51–0·59); 
p<0·0001
1·07 (1·03–1·11); 
p=0·0007
1·09 (1·04–1·13); 
p<0·0001
0·96 (0·94–0·99) 
p=0·0021
Diabetes 1·41 (1·39–1·44); 
p<0·0001
1·08 (1·05–1·12); 
p<0·0001
0·86 (0·81–0·91); 
p<0·0001
1·09 (1·053–1·13); 
p<0·0001
0·88 (0·85–0·92); 
p<0·0001
1·43 (1·40–1·46) 
p<0·0001
Age:male 0·81 (0·71–0·92); 
p=0·0010
0·74 (0·61–0·90); 
p=0·002
1·27 (0·91–1·78); 
p=0·1617
1·49 (1·20–1·86); 
p=0·0004
1·35 (1·04–1·75); 
p=0·0257
0·83 (0·71–0·98) 
p=0·0283
Age:lithium 0·69 (0·61–0·78); 
p<0·0001
0·86 (0·70–1·05); 
p=0·140
1·05 (0·73–1·52); 
p=0·7772
0·65 (0·51–0·83); 
p=0·0006
0·57 (0·42–0·77); 
p=0·0002
0·68 (0·58–0·80) 
p<0·0001
Male:lithium 0·90 (0·88–0·92); 
p<0·0001
1·13 (1·07–1·20); 
p<0·0001
0·94 (0·85–1·05); 
p=0·2635
0·77 (0·73–0·81); 
p<0·0001
0·90 (0·85–0·95); 
p<0·0001
0·91 (0·88–0·95) 
p<0·0001
Male 
<60 years
1·13 (0·98–1·29); 
p=0·083
1·81 (1·46–2·25); 
p<0·0001
1·25 (0·86–1·82); 
p=0·2508
0·78 (0·57–1·05); 
p=0·1007
0·54 (0·37–0·81); 
p=0·0023
1·05 (0·89–1·40) 
p=0·5382
Male 
≥60 years
1·40 (1·19–1·65); 
p<0·0001
1·70 (1·27–2·29); 
p=0·0004
1·61 (0·93–2·77); 
p=0·0904
1·73 (1·29–2·31); 
p=0·0002
0·93 (0·66–1·30); 
p=0·6606
1·30 (1·05–1·61) 
p=0·0158
Female 
<60 years
2·05 (1·86–2·25); 
p<0·0001
2·37 (2·10–2·69); 
p<0·0001
1·22 (0·95–1·57); 
p=0·1234
1·54 (1·29–1·83); 
p<0·0001
1·13 (0·90–1·41); 
p=0·2826
1·87 (1·67–2·09) 
p<0·0001
Female 
≥60 years
1·34 (1·17–1·52); 
p<0·0001
1·61 (1·33–1·95); 
p<0·0001
1·55 (1·15–2·09); 
p=0·004
1·92 (1·58–2·33); 
p<0·0001
1·39 (1·13–1·71); 
p=0·0016
1·26 (1·06–1·51) 
p=0·0102
Data are HR (95% CI). Decline in renal function is deﬁ ned by estimated glomerular ﬁ ltration rate less than 60 mL/min per 1·73 m². Hypothyroidism is deﬁ ned by thyrotropin 
activity greater than 5 mU/L. Hyperthyroidism is deﬁ ned by thyrotropin activity less than 0·2 mU/L. HR=hazard ratio. 
Table 2: HR for development of adverse eﬀ ects for subgroups of patients with at least two measurements of lithium concentration, by main eﬀ ects, 
two-factor interactions, and risks
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risk of approximately 0·5–2%. Until now, the risk factors 
for serious renal damage have been unknown. From our 
analysis, increased serum lithium concentrations and 
young age in women seem to be associated with 
increased risk of decline in renal function. Further work 
with patients, for whom more detailed clinical and 
pharmaceutical information is available, will be needed 
to identify those at highest risk.
Our results are consistent with those of other studies 
with smaller sample sizes or shorter follow-up periods. 
Results of a small retrospective study13 showed that use of 
lithium was associated with a modest decline in renal 
function and a very low risk of end-stage renal failure. 
Close and colleagues11 report a similar magnitude of risk 
(HR 2·5) in their larger retrospective cohort study. A 
case−control study reported that patients taking lithium 
had 6·9% higher plasma creatinine concentrations and 
7·3% lower estimated glomerular ﬁ ltration rate compared 
with patients with other psychiatric conditions, matched 
for age, sex and, primary-care practice.16 Study of a small 
prospective cohort,17 followed for 4 years, showed no 
signiﬁ cant diﬀ erence in renal function between patients 
treated with lithium and controls. Rej and colleagues17 
reported that patients who do not develop chronic kidney 
disease early in lithium treatment are less likely to 
develop disease at later stages. However, this hypothesis 
assumes that non-toxic concentrations of lithium are 
maintained, because we show that a higher median 
lithium level does seem to be a risk factor for renal failure.
The pathophysiology of lithium-induced renal failure is 
unclear but seems to be of a chronic tubulointerstitial 
nephropathy with lesions suggestive of focal segmental 
glomerulosclerosis.18 Renal cysts, which occur from the 
distal tubule and collecting ducts, might occur and can 
be visualised by MRI.19,20 Lithium-induced diabetes 
insipidus has been treated with the sodium channel 
blocker amiloride, with reasonable results.21,22 Preclinical 
results23 from rodents have also suggested that lithium-
induced renal ﬁ brosis might be reduced by treatment 
with amiloride.
All patients taking lithium therapy should have regular 
monitoring of renal function. The low risk of serious 
renal dysfunction should be balanced against the risks of 
the mood disorder and those of other mood stabilisers. 
From this study, young women and individuals who have 
a history of repeatedly high serum lithium concentrations 
seem to need closest monitoring. Data for lithium dosing 
and renal risk is scarce, so a sensible approach would be 
to minimise the dose of lithium used in general. The 
concentrations of lithium used in long-term treatment 
are usually lower than in treatment of acute mania, and 
these concentrations should be adhered to. Although the 
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Figure 3: Kaplan-Meier estimates of development of survival without reduced renal function
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evidence for dose-response with lithium therapy is 
sparse, higher concentrations of lithium might be more 
protective in the maintenance phase, but at the cost of 
more adverse eﬀ ects and lower adherence. Single daily 
dosing is probably better tolerated with respect to urinary 
frequency and is more likely to minimise the risk of 
nephrotoxic peak lithium levels.24
Lithium was associated with hypothyroidism (raised 
thyrotropin concentration), consistent with results 
reported by McKnight and colleagues.6 Individuals taking 
lithium, those aged more than 60 years, women, and 
people with diabetes all had a signiﬁ cantly raised risk of 
hypothyroidism (table 2). As with stage three chronic 
kidney disease, the risk of hypothyroidism seemed to be 
greatest at early stages of lithium treatment.
Lithium was not associated with hyperthyroidism 
(suppressed thyrotropin activity). Previous studies 
reporting hyperthyroidism in response to lithium 
treatment have been heterogeneous in size and follow-up, 
but this study is the largest long-term report so far. In 
Figure 4: Kaplan-Meier estimates of survival without development of hypothyroidism
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Decline in renal 
function
Hypothyroidism Hyperthyroidism Total serum calcium 
>2·6 mmol/L
Adjusted serum calcium 
>2·6 mmol/L
Age >60 years 3·85 (3·34–4·43); 
p<0·0001
1·40 (1·15-1·71); 
p=0·0010
2·20 (1·53–3·17); 
p<0·0001
1·99 (1·57–2·52); 
p<0·0001
3·19 (2·39–4·26); 
p<0·0001
Male 0·67 (0·58–0·76); 
p<0·0001
0·56 (0·46–0·69); 
p<0·0001
0·58 (0·40–0·85); 
p=0·0047
0·60 (0·46–0·78); 
p<0·0001
0·52 (0·37–0·71); 
p<0·0001
Higher than median 
lithium concentration
1·62 (1·41–1·85); 
p<0·0001
1·62 (1·35–1·94); 
p<0·0001
1·88 (1·33–2·66); 
p=0·0004
1·54 (1·22–1·95); 
p=0·0003
2·05 (1·54–2·72); 
p<0·0001
Length of time taking 
lithium
0·50 (0·44-0·58); 
p<0·0001
0·28 (0·23-0·34); 
p<0·0001
0·57 (0·40–0·82); 
p=0·0021
0·73 (0·58–0·92); 
p=0·0087
0·68 (0·51–0·90); 
p=0·0065
Diabetes 1·13 (0·94–1·37); 
p=0·1875
1·07 (0·82–1·40); 
p=0·6135
0·67 (0·38–1·20) 
p=0·1784
0·99 (0·73–1·36); 
p=0·9723
0·82 (0·56–1·21); 
p=0·3190
Data are HR (95% CI). Decline in renal function is deﬁ ned as estimated glomerular ﬁ ltration rate less than 60 ml/min per 1·73 m². Hypothyroidism is deﬁ ned as thyrotropin 
activity greater than 5 mU/L. Hyperthyroidism is deﬁ ned as thyrotropin activity less than 0·2 mU/L. HR=hazard ratio
Table 3: HR for renal failure, hypothyroidism, hyperthyroidism, and high serum calcium (total or adjusted) concentrations in patients taking lithium, by 
age, male sex, serum median lithium concentration, length of time between ﬁ rst and last lithium measurements, and diabetes
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patients taking lithium we noted an increased risk of 
development of hyperthyroidism in patients with higher 
median lithium concentrations.
Patients taking lithium, especially young women and 
those with high serum lithium concentrations, should 
have regular thyroid tests. Symptomatic hyperthyroidism 
should be treated, but it is unclear when hypothyroidism 
needs intervention, especially given the complex 
interaction between thyroid status and mood. In 
patients with treatment-resistant chronic low mood, 
treatment of biochemical (subclinical) hypothyroidism 
could be beneﬁ cial.
Little evidence is available to suggest what happens to 
thyroid function when lithium is withdrawn. Souza and 
colleagues25 reported that thyroid function might 
normalise if lithium is stopped, but no similar studies 
have been published to date.
Although we noted an increased risk of raised total 
serum calcium concentration with lithium treatment, 
the risk was not signiﬁ cant when adjusted serum calcium 
concentration was used. We noted signiﬁ cant interactions 
between age, sex, and lithium, and therefore considerable 
heterogeneity between the subgroups on the basis of sex 
and age groups with a cut-point of 60 years (table 3). 
Thus, women who are 60 years or more of age are at 
highest risk of high total and adjusted serum calcium 
concentrations. Whereas the risk for high total serum 
calcium concentration was increased in young women 
and elderly men, the risk was reduced in young men for 
adjusted serum calcium concentration.
We did not examine data to allow us to calculate the 
risk of a raised parathyroid hormone. Results of a 
previous meta-analysis6 of 14 observational studies of 
calcium and parathyroid hormone concentrations in 
patients taking lithium (739 patients) compared with 
controls (699 controls) showed a 10% increase in both 
serum calcium and parathyroid hormone concentrations 
in patients taking lithium. Similarly, investigators of a 
large cross-sectional study26 compared the serum 
calcium and parathyroid hormone concentrations of 
204 patients who had been taking lithium for at least 
6 years. Results showed a two-times increase in the rates 
of hypercalcaemia and hyperparathyroidism in cases 
compared with controls. In patients with bipolar 
disorder, serum parathyroid hormone and calcium 
concentrations have been reported27 to be higher in 
patients taking lithium compared with patients who do 
not take lithium. These results suggest that there is a 
positive association between lithium and hyper-
parathyroidism. The physiological mechanism of this 
association is open to debate. Besides the physical 
complications related to hypercalcaemia, the association 
of lithium with low mood is also well documented. This 
association is highly relevant to patients on lithium, who 
frequently have mood disorders that are diﬃ  cult to treat. 
As with thyroid disorders, these patients might beneﬁ t 
from returning even mildly raised calcium to within 
normal parameters. All patients on lithium therapy 
should be advised to have calcium measured at baseline 
and at least annually thereafter.
The strengths of this study are the large number of 
individuals and the length of follow-up, with many 
people having specimens analysed throughout a period 
of more than 20 years. The main limitations are the 
heterogeneity of the study population, the limited 
information on the clinical features of patients, why the 
specimens were taken, what proportion of patients 
taking lithium have bipolar versus unipolar disorder, or 
any information of the doses of lithium taken. We have 
had to assume that during the period of regular 
measurements of serum lithium concentration, the 
patient was taking the lithium therapy regularly. 
Intermittent lithium therapy during the study period 
might also have aﬀ ected the results, but this probably 
only concerns a few individuals and would indicate that 
the actual eﬀ ects are larger than we suggest. Although 
we controlled for previous biochemical abnormalities 
and diabetes, other confounders, such as use of other 
psychotropic medications, could have aﬀ ected the results. 
The fact that patients who took lithium had frequent 
measurements of serum creatinine concentration and 
thyrotropin activity would increase the likelihood that 
biochemical abnormalities were identiﬁ ed.
Patients receiving long-term lithium treatment will 
usually have a chronic mood disorder causing con siderable 
morbidity and premature mortality. Lithium remains the 
Panel: Research in context
Systematic review
The only comprehensive systematic review of the eﬀ ect of lithium therapy on renal, 
thyroid, and parathyroid function was published by The Lancet in 2012.6 The main 
ﬁ ndings of this review were that lithium is associated with reduced urinary concentrating 
ability, hypothyroidism, and hyperparathyroidism. There was little evidence for a clinically 
signiﬁ cant reduction in renal function and the absolute risk of renal failure was low. This 
systematic review was completed only shortly before this study began and therefore we 
judged no further update was needed.
Interpretation
With this retrospective cohort study, we set out to determine the strength of association 
between lithium therapy and renal, thyroid, and parathyroid dysfunction. This large study 
includes serum measurements given by 500 000 individuals during a 20 year period. The 
results show that lithium is associated with a decline in renal function (stage three chronic 
kidney disease), especially in young women and those with higher median lithium 
concentrations. Patients who are vulnerable to the nephrotoxic eﬀ ect of lithium show a 
decline in renal function at an early stage of treatment. This ﬁ nding is also true when test 
results were adjusted for the presence of hyperglycaemia. Lithium is also associated with 
hypothyroidism and, to a lesser extent, hypercalcaemia; the magnitude of these disorders 
are consistent with that of the above systematic review.6 Our ﬁ ndings suggest that close 
monitoring of adverse eﬀ ects in all patients taking lithium is essential and that clinicians 
should work hard to use the lowest eﬀ ective dose of lithium. This study is the ﬁ rst to 
suggest some patient factors (sex, age) that might aﬀ ect susceptibility to lithium 
nephrotoxicity; this area needs further exploration to allow as many patients as possible 
to beneﬁ t from the gold standard mood stabiliser for bipolar disorder. 
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standard mood stabiliser for use in bipolar disorder and 
also reduces the risk of suicide.4,28 The evidence that 
lithium can adversely aﬀ ect endocrine systems is clear, but 
clinically signiﬁ cant conditions are either rare (renal 
function) or treatable (thyroid, parathyroid function). 
Other available drug treatments have signiﬁ cant side 
eﬀ ects and many are not recommended for use in young 
women. Lithium remains a key treatment, although its use 
needs monitoring and a safety-conscious approach is 
needed.28 Young women and those with episodes of higher 
lithium serum levels are most at risk, and the risk often 
seems to be highest at early stages of treatment. Methods 
of early identiﬁ cation of adverse eﬀ ects and preventive 
strategies need improvement, and the risks and beneﬁ ts of 
lithium withdrawal in patients who have developed adverse 
eﬀ ects, but whom continue to derive clinical beneﬁ t, 
should be studied further.
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